Prediction of tacrolimus metabolism and dosage requirements based on CYP3A4 phenotype and CYP3A5(*)3 genotype in Chinese renal transplant recipients.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 26924289)

Published in Acta Pharmacol Sin on February 29, 2016

Authors

Xi Luo1,2,3, Li-jun Zhu4, Ning-fang Cai5, Li-yun Zheng2, Ze-neng Cheng2

Author Affiliations

1: School of Life Sciences, Central South University, Changsha 410083, China.
2: School of Pharmaceutical Sciences, Central South University, Changsha 410013, China.
3: The State Key Laboratory of Medical Genetics, Central South University, Changsha 410078, China.
4: Research Center of National Health Ministry on Transplantation Medicine Engineering and Technology, the 3rd Affiliated Hospital of Xiangya Medical Institute, Central South University, Changsha 410013, China.
5: Department of Pharmacy, Zhangzhou Municipal Hospital of Fujian Province, Zhangzhou 363000, China.

Associated clinical trials:

The Biomarker for Immunosuppressive Agents Metabolism in Chinese Renal Transplant Recipients | NCT01699360

Articles cited by this

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet (2001) 5.80

In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. Clin Pharmacol Ther (2012) 3.51

Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther (2001) 2.62

Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev (1997) 1.47

Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant (2003) 1.34

An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther (2006) 1.22

Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol (2003) 1.21

CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther (2006) 1.10

Identification of polymorphisms in the 3'-untranslated region of the human pregnane X receptor (PXR) gene associated with variability in cytochrome P450 3A (CYP3A) metabolism. Xenobiotica (2010) 1.06

Evaluation of 6β-hydroxycortisol, 6β-hydroxycortisone, and a combination of the two as endogenous probes for inhibition of CYP3A4 in vivo. Clin Pharmacol Ther (2011) 0.96

CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels. Clin Pharmacol Ther (2004) 0.86

Evaluation of CYP3A activity in humans using three different parameters based on endogenous cortisol metabolism. Acta Pharmacol Sin (2009) 0.80

Simultaneous determination of cortisol, cortisone, 6β-hydroxycortisol and 6β-hydroxycortisone by HPLC. J Chromatogr Sci (2015) 0.80

Determination of 13-O-demethyl tacrolimus in human liver microsomal incubates using liquid chromatography-mass spectrometric assay (LC-MS). J Chromatogr B Analyt Technol Biomed Life Sci (2005) 0.80